What is NuSirt Sciences?
NuSirt Sciences operates at the intersection of biotechnology and metabolic health, focusing on the complex interplay between overnutrition, aging, and chronic disease. The company specializes in identifying and validating natural compounds and pharmaceutical agents that mitigate conditions such as metabolic-associated fatty liver disease, obesity, type 2 diabetes, and hypertension. By leveraging a dual-track approach—developing combination therapies like TRIPLN and dietary supplements such as LEUSIX—NuSirt Sciences provides a comprehensive suite of solutions for both clinical and preventative health management. Their market position is defined by rigorous scientific validation, bridging the gap between early-stage research and practical, patient-centric healthcare applications.
How much funding has NuSirt Sciences raised?
NuSirt Sciences has raised a total of $20.6M across 4 funding rounds:
Series B
$9.1M
Series A
$3.5M
Series C
$6M
Private Equity
$2M
Series A (2014): $3.5M with participation from William Guttman, Mountain Group Capital, and Tennessee Community Ventures Fund
Series B (2014): $9.1M, investors not publicly disclosed
Series C (2015): $6M supported by TriStar Technology Ventures, Hatteras Venture Partners, and Mountain Group Partners
Private Equity (2016): $2M, investors not publicly disclosed
Key Investors in NuSirt Sciences
Hatteras Venture Partners
A venture capital firm specializing in transformative biotech, MedTech, and HealthTech investments, providing both capital and strategic operational support.
Mountain Group Partners
A Nashville-based firm focused on early-stage Life Sciences and technology, known for taking an active, long-term role in shaping company growth.
TriStar Technology Ventures
An investment firm operating within the software and IT services sector, providing essential backing for technology-driven healthcare innovation.
What's next for NuSirt Sciences?
With the recent strategic investment, NuSirt Sciences is well-positioned to accelerate its clinical trial milestones and expand the commercial reach of its metabolic health portfolio. The company's roadmap likely involves scaling its research operations to further validate the efficacy of its lead candidates in larger patient cohorts. As the firm transitions from a research-heavy entity to a more mature commercial organization, the focus will shift toward regulatory navigation and strategic partnerships with healthcare providers. This growth phase is critical for establishing NuSirt as a leader in the cardiometabolic space, ensuring that their innovative therapies reach the individuals who need them most while maintaining the high scientific standards that have attracted significant institutional backing.
See full NuSirt Sciences company page
